Combination Of Viral And Bacterial Antigens (e.g., Multivalent Viral And Bacterial Vaccine, Etc.) Patents (Class 424/201.1)
  • Patent number: 10632189
    Abstract: Provided herein are compositions, combinations, and methods comprising Canine Respiratory Coronavirus (CRCoV), which are effective in treating or preventing respiratory infections associated secondary pathogens, such as Bordetella bronchiseptica, in animals.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: April 28, 2020
    Assignee: Zoetis Services LLC
    Inventors: Shelly Lynn Shields, Omar Yousif Abdelmagid
  • Patent number: 10258688
    Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: April 16, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Billy M. Hargis, Neil R. Pumford, Marion Morgan, Srichaitanya Shivaramaiah, Guillermo Tellez-Isaias, Amanda Wolfenden
  • Patent number: 10138494
    Abstract: A mammalian cell co-transfect with an expression plasmid comprising T7 promoter and an open reading frame (ORF) of target antigen, and a vT7 recombinant vaccinia virus expressing T7 polymerase. The entire antigen expressing cell is used as a carrier of the target antigen for preparing a vaccine or diagnostic agent, and screening monoclonal antibodies.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 27, 2018
    Assignee: FORMOSA BIOMEDICAL INC.
    Inventor: Shun-Wen Ko
  • Patent number: 10080795
    Abstract: The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: September 25, 2018
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Sebastian Ulbert, Christiane Wetzel
  • Patent number: 9987348
    Abstract: This invention provides a vaccine composition for protecting pigs against PCV2, including a highly virulent porcine circovirus type 2b (PCV2b) divergent strain, the composition including a PCV2b divergent ORF2 polypeptide, wherein the ORF2 polypeptide comprises Leucine (L) at position 89, Threonine (T) at position 90, and Aspargine (N) at position 134, according to the numbering of SEQ ID NO: 1 herein.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 5, 2018
    Assignee: Zoetis Services LLC
    Inventors: Gregory Paul Nitzel, David Ewell Slade
  • Patent number: 9969777
    Abstract: The present invention provides an infectious bronchitis virus (IBV) spike protein (S protein) which is based on an S protein from an IBV strain with restricted tissue tropism, but which comprises the sequence XBBXBX in the part of the S2 protein corresponding to residues 686 to 691 of the sequence given as SEQ ID No. 2, where B is a basic residue and X is any amino acid; and which comprises at least one of the following amino acid substitutions with reference to the position numbering of SEQ ID NO:2: Leucine (L) to Phenylalanine (F) at position 578 Asparagine (N) to Serine (S) at position 617 Asparagine (N) to Serine (S) at position 826 Leucine (L) to Phenylalanine (F) at position 857 and Isoleucine (I) to Valine (V) at position 1000 such that an IBV virus comprising the S protein has extended tissue tropism. The present invention also provides a virus comprising such an S protein.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: May 15, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Paul Britton, Erica Bickerton
  • Patent number: 9878027
    Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: January 30, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
  • Patent number: 9526780
    Abstract: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: December 27, 2016
    Assignee: Intervet Inc.
    Inventors: Zhisong Qiao, Kevin O'Connell
  • Patent number: 9260691
    Abstract: The present invention provides a method for identifying or generating an attenuated mycoplasma bacterium, which bacterium comprises a mutation in at least one gene as listed and use of the bacterium in a vaccine for eliciting protective immunity against mycoplasma or for detecting infection by said bacterium.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: February 16, 2016
    Assignee: BIOPROPERTIES PTY LTD
    Inventors: Rima Youil, Youssef Abs El-Osta
  • Patent number: 9211320
    Abstract: Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: December 15, 2015
    Assignee: VaxInnate Corporation
    Inventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
  • Patent number: 9205138
    Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: December 8, 2015
    Assignee: VaxInnate Corporation
    Inventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
  • Patent number: 9186398
    Abstract: The invention relates to live attenuated parvoviruses, their uses, vaccines comprising such live attenuated parvoviruses, as well as methods for their production.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: November 17, 2015
    Assignee: Intervet Inc.
    Inventor: Norman Spibey
  • Patent number: 9163068
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: October 20, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20150147354
    Abstract: A method of making a blood product for administration to patient animals to prevent or mitigate a specific condition or disease includes pre-treating one or more donor animals, collecting blood from the donor animals after pre-treatment, and processing the collected blood to make a blood product for administering to one or more patient animals. The pre-treatment step is designed to optimize the levels of one or more components in the blood that play a role in preventing or treating a specific condition or disease.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Applicant: CENTRAL BIOMEDIA, INC.
    Inventors: TAMMI SUE EPP, JEFFERY SCOTT PENDERGRAFT, DONALD E. MYERS, WILLIAM G. SKELLY
  • Publication number: 20150140033
    Abstract: The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens Type alpha toxins, or any combination thereof. The present invention further describes methods of using with these vaccines to protect animals against clostridial diseases. The present invention also describes methods of making these vaccines.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: Huchappa Jayappa, Kevin O'Connell
  • Publication number: 20150125486
    Abstract: An immunogenic composition comprising a diphtheria toxoid, a tetanus toxoid, a pertussis toxoid, an aluminium salt adjuvant, and a TLR4 agonist. Preferably, the TLR4 agonist and/or at least one of the toxoids is/are adsorbed to the aluminium salt adjuvant.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 7, 2015
    Inventors: Simone Bufali, Barbara Baudner, Derek O'Hagan, Manmohan Singh
  • Publication number: 20150125487
    Abstract: The present invention provides attenuated P. multocida strains that elicit an immune response in animal P. multocida, compositions comprising said strains, methods of vaccination against P. multocida, and kits for use with such methods and compositions. The invention further provides novel, genetically-engineered mutations in P. multocida hyaD and nanPU genes, which are useful in the production of novel attenuated P. multocida bacterial strains.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 7, 2015
    Applicant: MERIAL LIMITED
    Inventors: Paulraj Kirubakaran Lawrence, Russell F. Bey
  • Patent number: 9023366
    Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: May 5, 2015
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Publication number: 20150086586
    Abstract: Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 ?g per human dose.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Inventor: Jan Theunis POOLMAN
  • Publication number: 20150050309
    Abstract: The present invention relates, in-general, to Human immunodeficiency virus (HIV), and in particular to a carbohydrate-based vaccine for HIV and to methods of making and using same.
    Type: Application
    Filed: July 16, 2014
    Publication date: February 19, 2015
    Applicants: Duke University, University of Kansas
    Inventors: Barton F. HAYNES, Heather Desaire, Eden P. Go
  • Publication number: 20150037370
    Abstract: This invention provides diatom-based vaccines.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 5, 2015
    Applicants: SYNAPTIC RESEARCH, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Lynette B. Corbeil, Mark Hildebrand, Roshan Shrestha, Aubrey Davis, Rachel Schrier, George A. Oyler, Julian N. Rosenberg
  • Publication number: 20150037368
    Abstract: The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising a Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and a polyanionic polymer, and (ii) a second composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8.
    Type: Application
    Filed: October 8, 2014
    Publication date: February 5, 2015
    Inventors: Nathalie Marie-Josephe GARCON, Dominique LEMOINE, Florence Emilie Jeanne Francoise WAUTERS
  • Patent number: 8945582
    Abstract: The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain adequate or improved level of protection against polio.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Patent number: 8932605
    Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: January 13, 2015
    Assignee: VaxInnate Corporation
    Inventors: Langzhou Song, Lynda G. Tussey, Alan R. Shaw, Robert S. Becker, Yi Zhang, Scott W. Umlauf, Ge Liu
  • Patent number: 8916173
    Abstract: Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 ?g per human dose.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: December 23, 2014
    Assignee: Crucell Holland B.V.
    Inventor: Jan Theunis Poolman
  • Publication number: 20140363466
    Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Carol L. RINEHART, Craig JONES, Judy MYERS-KUHNHOFF, Wayne COLE, William Charles OHNESORGE
  • Publication number: 20140341947
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Jeremy KROLL, Mike ROOF
  • Publication number: 20140322297
    Abstract: A composition comprising a drug or pharmaceutically active agent and a bioadhesive delivery system provides for the oral delivery of a vaccine to animals, particularly aquatic animals.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 30, 2014
    Inventors: MOTI HAREL, Brian Carpenter
  • Publication number: 20140322267
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Gregory HAIWICK, Luis HERNANDEZ, Wesley Scott JOHNSON, Christine Margaret MUEHLENTHALER, Eric Martin VAUGHN
  • Patent number: 8871221
    Abstract: Compositions that include at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one member selected from the group consisting of a Den1 viral envelope protein, a Den2 viral envelope protein, a Den3 viral envelope protein and a Den4 viral envelope protein are employed in methods to stimulate a protective immune response in a subject.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: October 28, 2014
    Assignee: Vaxinnate Corporation
    Inventors: Thomas J. Powell, Valerian Nakaar, Langzhou Song, James W. Huleatt, William F. McDonald, Duane D. Hewitt
  • Patent number: 8865182
    Abstract: The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 21, 2014
    Assignee: Paxvax, Inc.
    Inventors: Timothy P. Mayall, Jeff Alexander
  • Publication number: 20140302087
    Abstract: When preparing HBsAg for use in a combination vaccine, it is known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: Novartis Vaccines and Diagnostics, SRL
    Inventor: Mario CONTORNI
  • Patent number: 8852577
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 7, 2014
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • Publication number: 20140294935
    Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 2, 2014
    Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
  • Patent number: 8846054
    Abstract: The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: September 30, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Carol L. Rinehart, Craig Jones, Judy Myers-Kuhnhoff, Wayne Cole, William Charles Ohnesorge
  • Patent number: 8821889
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Patent number: 8821885
    Abstract: The invention is directed to immunogenic compositions, and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating microbial infection, including, for example, influenza, or one or more symptoms thereof.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: September 2, 2014
    Assignee: Longhorn Vaccines & Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 8795681
    Abstract: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: August 5, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
  • Publication number: 20140205631
    Abstract: The present invention provides angiotensin peptide compositions and methods for use of the compositions in vaccination.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Inventors: Robert LARSEN, Kathleen E. RODGERS, Gere S. DIZEREGA
  • Patent number: 8784825
    Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: July 22, 2014
    Assignee: Taiga Biotechnologies, Inc.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 8778348
    Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: July 15, 2014
    Assignee: iBio Inc.
    Inventors: Elisabeth Knapp, Vidadi Yusibov
  • Patent number: 8753646
    Abstract: The invention provides a process for producing a combined vaccine containing an inactivated Sabin strain of poliovirus, a Bordetella pertussis protective antigen, a diphtheria toxoid and a tetanus toxoid, the process including a step of producing a high-titer Sabin strain poliovirus. The inventive process for producing a combined vaccine, including a step of culturing, in the presence of from about 4 g/L to about 6 g/L of a microcarrier, Vero cells to be inoculated with a Sabin strain of poliovirus, is useful as a process for efficiently producing a combined vaccine containing an inactivated Sabin strain of poliovirus.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: June 17, 2014
    Assignees: Japan Poliomyelitis Research Institute, Takeda Pharmaceutical Company Limited
    Inventors: Shinobu Abe, Bunsichi Simizu
  • Publication number: 20140154265
    Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.
    Type: Application
    Filed: September 24, 2013
    Publication date: June 5, 2014
    Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
  • Publication number: 20140147475
    Abstract: The present invention pertains to a vaccine comprising live attenuated Pasteurella multocida bacteria for protection of a ruminant against pneumonia caused by Pasteurella multocida by administration of the vaccine to the upper respiratory tract of the ruminant via atomisation of the vaccine. The invention also pertains to a method to use the vaccine to protect a ruminant against pneumonia caused by Pasteurella multocida bacteria.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 29, 2014
    Inventor: Antonius Arnoldus Christiaan Jacobs
  • Publication number: 20140134202
    Abstract: An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine.
    Type: Application
    Filed: December 13, 2011
    Publication date: May 15, 2014
    Applicant: FOLIA BIOTECH INC.
    Inventors: Denis LECLERC, Nathalie MAJEAU, Constantino Roberto LOPEZ-MACIAS, III, Alain LAMARRE
  • Publication number: 20140127259
    Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Carol L. RINEHART
  • Publication number: 20140120135
    Abstract: The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally Mycoplasma hyopneumoniae and in an aqueous composition for reducing fever induced by the biological antigens present in the aqueous composition when the composition is administered to a subject animal.
    Type: Application
    Filed: June 26, 2012
    Publication date: May 1, 2014
    Inventor: Erwin Mombarg
  • Publication number: 20140112950
    Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
    Type: Application
    Filed: March 2, 2012
    Publication date: April 24, 2014
    Inventors: Manmohan Singh, Barbara Baudner, David Skibinski
  • Publication number: 20140105930
    Abstract: Methods for stimulating immune responses in a bovine animal susceptible to infection by Leptospira hardjo-bovis are disclosed. In the methods, a composition of inactivated L. hardjo-bovis and an adjuvant is administered to the animal within about 4 weeks of birth. The immune responses stimulated in the animal prevent or shorten the duration of a subsequent L. hardjo-bovis infection. The immune response is effective for at least a year.
    Type: Application
    Filed: June 8, 2012
    Publication date: April 17, 2014
    Applicant: NOVARTIS AG
    Inventor: Eric Springer
  • Patent number: 8691234
    Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: April 8, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato